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Br J Pharmacol. 2019;1–15.Background and Purpose: Triptans are 5‐HT1B/1D receptor agonists (that also dis-
play 5‐HT1F receptor affinity) with antimigraine action, contraindicated in patients
with coronary artery disease due to their vasoconstrictor properties. Conversely,
lasmiditan was developed as an antimigraine 5‐HT1F receptor agonist. To assess the
selectivity and cardiovascular effects of lasmiditan, we investigated the binding,
functional activity, and in vitro/in vivo vascular effects of lasmiditan and compared it
to sumatriptan.
Experimental Approach: Binding and second messenger activity assays of
lasmiditan and other serotoninergic agonists were performed for human 5‐HT1A, 5‐
HT1B, 5‐HT1D, 5‐ht1E, 5‐HT1F, 5‐HT2A, 5‐HT2B, and 5‐HT7 receptors, and the results
were correlated with their potency to constrict isolated human coronary arteries
(HCAs). Furthermore, concentration–response curves to lasmiditan and sumatriptan
were performed in proximal and distal HCA, internal mammary, and middle meningeal
arteries. Finally, anaesthetized female beagle dogs received i.v. infusions of lasmiditan
or sumatriptan in escalating cumulative doses, and carotid and coronary artery
diameters were measured.
Key Results: Lasmiditan showed high selectivity for 5‐HT1F receptors. Moreover,
the functional potency of the analysed compounds to inhibit cAMP increase through
5‐HT1B receptor activation positively correlated with their potency to contract HCA.
In isolated human arteries, sumatriptan, but not lasmiditan, induced contractions.
Likewise, in vivo, sumatriptan decreased coronary and carotid artery diameters at
clinically relevant doses, while lasmiditan was devoid of vasoconstrictor activity at
all doses tested.- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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CompanyConclusions and Implications: Lasmiditan is a selective 5‐HT1F receptor agonist
devoid of vasoconstrictor activity. This may represent a cardiovascular safety advan-
tage when compared to the triptans.What is already known
• Lasmiditan is effective in the acute treatment of migraine.
What this study adds
• Lasmiditan selectively activates the human 5‐HT1F
receptor and is devoid of vasoconstrictor activity.
What is the clinical significance
• The lack of vasoconstriction may represent a safety
advantage for migraine patients with cardiovascular
disease.1 | INTRODUCTION
Migraine is a neurological disease characterized by throbbing unilateral
headaches of moderate to severe intensity, accompanied by nausea,
vomiting, photophobia, and/or phonophobia (Headache Classification
Committee of the International Headache Society, 2018). It has an esti-
mated prevalence of 15% in the global population, with women being
three timesmore affected thanmen (Kurth et al., 2016; Vos et al., 2012).
Currently, the specific therapies for acute antimigraine treatment
are the triptans, selective 5‐HT1B/1D receptor agonists that also
display varying levels of 5‐HT1F receptor affinity. Unfortunately, not
all patients respond to triptans (Diener & Limmroth, 2001), and they
are contraindicated in patients with cardiovascular disease, due to their
contractile properties via activation of 5‐HT1B receptors in coronary
arteries (Chan et al., 2014; Dodick et al., 2004; Labruijere et al., 2015;
MaassenVanDenBrink, Reekers, Bax, Ferrari, & Saxena, 1998). There-
fore, there is a need for novel antimigraine drugs for the patients that
do not respond to the current available treatments, but also, for those
patients with cardiovascular disease.
Based on results from preclinical studies, the 5‐HT1F receptor ago-
nist, lasmiditan, was developed for acute antimigraine treatment (John-
son et al., 1997; Nelson et al., 2010) and Phase III trials showed positive
results (Goadsby et al., 2019; Kuca, Silberstein, Wietecha, Berg, Dozier,
& Lipton, 2018). Considering the increased cardiovascular risk of
migraine patients (Buse, Reed, Fanning, Kurth, & Lipton, 2017; Kurth
et al., 2016; Sacco&Kurth, 2014; Schurks et al., 2009), and the presence
of 5‐HT1F receptors in the vasculature (Bouchelet, Case, Olivier, &
Hamel, 2000; Bouchelet, Cohen, Case, Séguéla, & Hamel, 1996; Nilsson
et al., 1999), it is important to determine whether lasmiditan lacks affin-
ity for human 5‐HT1B receptors and whether activation of 5‐HT1F
receptors will result in vasoconstrictive responses. On this basis, the
aim of this study was to investigate the pharmacological properties of
lasmiditan and in particular (a) to assess the selectivity and functional
activity of lasmiditan, triptans, and other 5‐HT receptor ligands on var-
ious human 5‐HT receptors; (b) to analyse its potential to induce vaso-
constriction in in vitro (isolated human proximal and distal coronary,
internal mammary, and middle meningeal arteries) and in vivo (carotid
and coronary artery diameters in anesthetized dogs) preclinical models;
and (c) to compare our findings with lasmiditan to those obtained with
sumatriptan, one of the most prescribed triptans to acutely treat
migraine.
We hypothesize that, unlike sumatriptan, lasmiditan selectively
activates the human 5‐HT1F receptor and does not induce vasocon-
striction in the above in vitro (including human coronary arteries) and
in vivo vascular models.2 | MATERIALS AND METHODS
2.1 | Cell membrane preparation
CHO‐K1 cells (RRID:CVCL_0214) expressing the human recombinant
5‐HT1A, 5‐HT1B, 5‐HT1D, 5‐ht1E, 5‐HT1F, 5‐HT2A, 5‐HT2B, or 5‐HT7
receptors were grown prior to the test in media without antibiotic at
Ogeda SA (Gosselies, Belgium). Cells were prepared using a protocol
from Ogeda. In brief, cells were harvested by scraping from the culture
vessels in ice‐cold Ca2+‐ andMg2+‐free PBS. The cells were then centri-
fuged for 10 min at 5,000×g and 4°C, and the pellets were suspended in
buffer A (15‐mMTris–HCl pH 7.5, 2‐mMMgCl2, 0.3‐mM EDTA, and 1‐
mM EGTA) and homogenized in a glass–glass homogenizer. The crude
membrane fraction was collected by two consecutive centrifugation
steps at 35,000×g and 4°C for 30 min separated by a washing step in
buffer A. The final membrane pellet was suspended in buffer B (75‐
mM Tris–HCl pH 7.5, 12.5‐mM MgCl2, 0.3‐mM EDTA, 1‐mM EGTA,
and 250‐mM sucrose) and flash‐frozen in liquid nitrogen. Protein con-
tent was determined by the BCA method (Interchim, UP40840A).2.2 | Radioligand binding competition assay
Competition binding was performed in duplicate in the wells of a
96‐well plate containing binding buffer (optimized for each receptor),
cell membrane extracts (approximately 20,000 cells distributed in the
96‐well plate), radiotracer, and test agonist. Non‐specific binding was
determined by co‐incubation with 200‐fold excess of competitor.
Cells were incubated and exposed to varying concentrations (1 pM
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were incubated in a final volume of 0.1 ml and then filtered over
Unifilter plates (Perkin Elmer, Massachusetts, USA) pretreated for
2 hr to limit tracer non‐specific binding. Filters were washed five
times with 0.5 ml of ice‐cold washing buffer (tris 50 mM pH 7.4)
and 50 μl of Microscint 20 (Perkin Elmer) were added to each filter.
The plates were incubated 15 min at room temperature on an orbital
shaker and then counted with a TopCount™ (Perkin Elmer) for 1 min
per well.
2.2.1 | cAMP HTRF assay for Gi coupled receptors
Concentration–response curves were performed in parallel with the
agonists. For agonist tests, 12 μl of cells were mixed with 6 μl of the
test compound (at increasing concentrations) and 6 μl of forskolin
and then incubated for 30 min at room temperature. After addition
of the lysis buffer and 1‐hr incubation, cAMP concentrations were
estimated according to the manufacturer specification with the HTRF
kit (Cisbio International, Codelet, France). In brief, increasing concen-
trations of agonists were added to stably transfected cells in buffer
in an Optiplate (PerkinElmer Life Sciences, Massachusetts, USA). The
plates were incubated, and cells were then lysed by the addition of
HTRF reagents (cAMP‐Cryptate and anti‐cAMP‐d2 reagents) and
diluted in lysis buffer, followed by incubation at room temperature.
As 5‐HT1B receptors have been reported in naïve CHO‐K1 cells
(George, Bungay, & Naylor, 1997), we also tested 5‐
carboxamidotryptamine (5‐CT, the reference agonist for the 5‐HT1B
receptor), in CHO‐K1 cells transfected with a non‐5‐HT, GPCR.
2.2.2 | cAMP HTRF assay for Gs coupled receptors
Concentration–response curves were performed in parallel. For ago-
nist tests, 12 μl of cells were mixed with 12 μl of the test compound
at increasing concentrations and then incubated 30 min at room tem-
perature. After addition of the lysis buffer and 60 min incubation,
cAMP concentrations were estimated, according to the manufacturer
specification, with the HTRF kit (Cisbio International, Codelet, France).
Briefly, increasing concentrations of agonists were added to stably
transfected cells in buffer in an Optiplate (PerkinElmer Life Sciences).
The plates were incubated, and cells were then lysed by the addition
of HTRF reagents (cAMP‐Cryptate and anti‐cAMP‐d2 reagents) and
diluted in lysis buffer, followed by incubation at room temperature.
2.2.3 | IPOne HTRF assay
The assay was performed on adherent cells. For agonist testing, the
medium was removed and 20 μl of assay buffer plus 20 μl of the stud-
ied agonist or the reference agonist were added in each well. The plate
was incubated for 60 min at 37°C with 5% CO2. IP1‐D2 reagent and
anti‐IP1 cryptate reagents were dispensed in the wells, and IP1 con-
centrations were then measured following the manufacturer instruc-
tions (IPOne HTRF assay kit; Cisbio International, Codolet, France).
In brief, increasing concentrations of agonists were added to stablytransfected cells in buffer in an Optiplate (PerkinElmer Life Sciences).
The plates were incubated, and cells were then lysed by the addition
of HTRF reagents (IP1‐D2 reagent and anti‐IP1 cryptate reagents)
and diluted in lysis buffer, followed by incubation at room
temperature.
2.2.4 | GTPγ
35S assay
For agonist testing, membrane extracts expressing the receptor of
interest was mixed with GDP. In parallel, GTPγ[
35S] was mixed with
the beads just before starting the reaction. The following reagents
were successively added in the wells of an Optiplate (Perkin Elmer):
50 μl of reference ligand, 10 μl of assay buffer, 20 μl of the cells:
GDP mix, and 20 μl of the GTPγ[
35S]: beads mix. The plate was incu-
bated for 60 min, then centrifuged and counted with a PerkinElmer
TopCount™ reader.
2.2.5 | Agonists tested
5‐HT (serotonin), 5‐CT, ergotamine, sumatriptan, zolmitriptan,
naratriptan, rizatriptan, almotriptan, eletriptan, frovatriptan,
donitriptan, avitriptan, alniditan, lasmiditan, LY334370, and
LY344864 were tested. The radioligands and reference compounds
used for the radioligand and second messenger studies are specified
in Tables S1 and S2.2.3 | Human isolated arteries
2.3.1 | Coronary arteries
Coronary arteries were obtained from six “heart beating” organ donors
(three males and three females; 48–62 years), who died of non‐cardiac
disorders less than 24 hr before the tissue was taken to the laboratory.
The hearts were provided by the Heart Valve Bank Beverwijk Bank
(nowadays ETB‐BISLIFE Tissue Bank) at that time still located in Rot-
terdam, from Dutch post‐mortem donors, after donor mediation via
Bio Implant Services/Eurotransplant Foundation (Leiden, The Nether-
lands), following removal of the aortic and pulmonary valves for homo-
graft valve transplantation. All donors gave permission for research.
Immediately after circulatory arrest, the hearts were stored at 4°C in
a sterile organ protecting solution and were brought to the laboratory
within the first 24 hr of death. After arrival at the laboratory, the right
proximal (internal diameter 3–5 mm) and distal (internal diameter 0.5–
1 mm) portions of the coronary artery were dissected and placed in a
cold, oxygenated (95% O2/5% CO2) Krebs buffer solution of the fol-
lowing composition: 118‐mM NaCl, 4.7‐mM KCl, 2.5‐mM CaCl2, 1.2‐
mMMgSO4, 1.2‐mM KH2PO4, 25‐mMNaHCO3, and 8.3‐mM glucose;
pH 7.4.
2.3.2 | Internal mammary arteries
Internal mammary arteries (internal diameter 2–3 mm) were obtained
perioperatively from 18 patients (16 males and two females; 51–
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ately placed in a sterile organ‐protecting solution and was brought to
the laboratory within 15 min. Subsequently, the artery was cleaned of
connective tissue and placed in a cold, oxygenatedKrebs buffer solution
(for composition, see above).2.3.3 | Middle meningeal arteries
Middle meningeal arteries (internal diameter 0.5–1.5 mm) were
obtained from the dura mater of six patients (two males and four
females; 12–68 years) who underwent neurosurgery. The dura mater,
together with a small piece of the meningeal artery, was collected in a
sterile organ‐protecting solution and immediately transported to the
laboratory. The dura mater and connective tissue were dissected, and
the arterywas placed in a cold, oxygenatedKrebs solution of the follow-
ing composition: 119‐mMNaCl, 4.7‐mM KCl, 1.25‐mM CaCl2, 1.2‐mM
MgSO4, 1.2‐mM KH2PO4, 25‐mM NaHCO2, and 11.1‐mM glucose;
pH 7.4.
All arteries were used on the same day or stored overnight and
used the following day for functional experiments. The studies on cor-
onary arteries were approved by the Scientific Advisory Board of the
Rotterdam Heart Valve Bank. The Medical Ethics Committee of the
Erasmus Medical Center, Rotterdam, approved the study protocols
with regard to mammary arteries and middle meningeal arteries.2.4 | Isometric tension measurements
Proximal coronary arteries were cut into segments of 2‐ to 4‐mm
length, excluding distinct, macroscopically visible atherosclerotic
lesions. The segments were mounted on stainless steel hooks in 15‐
ml organ baths filled with oxygenated Krebs buffer solution at 37°C.
After equilibration for at least 30 min and a wash every 15 min, the
vessel segments were stretched to a stable tension of about 15 mN,
with the optimal pre‐tension as determined earlier (Labruijere et al.,
2015). Changes in tissue tension were measured with an isometric
force transducer (Harvard, South Natick, MA, USA) and recorded on
a flatbed recorder (Servogor 124, Goerz, Neudorf, Austria).
The distal coronary, internal mammary, and middle meningeal
arteries were cut into circular 1‐ 2‐mm‐long segments and mounted
in Mulvany myographs (Danish Myo Technology, Aarhus, Denmark)
between two parallel small stainless‐steel wires (40‐μm calibre). All
the baths were filled with warm Krebs buffer (37°C) and aerated with
carbogen. The tension was normalized to 90% of l100 for all segments,
the diameter when transmural pressure equals 100 mm Hg (Mulvany
& Halpern, 1977). Data of these vessels were recorded using a
LabChart data acquisition system (AD Instruments Ltd, Oxford, UK).2.4.1 | Experimental protocols
A paired parallel set up (i.e., all compounds were tested in different
segments obtained from the same artery) was used. Initially, all seg-
ments were exposed to 30‐mM KCl to “prime” the tissue for stablecontractions. After washout, the tissue was exposed to 100‐mM KCl
to determine the maximal contractile response. After further washout,
a concentration–response curve to vehicle, sumatriptan, or lasmiditan
was constructed, using whole logarithmic steps from 1 nM up to
10 μM. After finishing the curve and washing several times until
reaching equilibrium, the functional integrity of the endothelium was
verified by observing relaxation to substance P (10 nM; coronary
and meningeal arteries) or bradykinin (1 μM; mammary arteries), after
precontraction with the TxA2 analogue U46619 (10–100 nM; Chan
et al., 2014; Labruijere et al., 2015).
Furthermore, in the internal mammary arteries, a concentration–
response curve to lasmiditan and sumatriptan was also constructed
after adding threshold concentrations of U46619 (i.e., concentrations
eliciting a contraction of ~10% of 100‐mM KCl response, determined
in quarter logarithmic steps), used to unmask contractile properties of
some agonists in the presence of an increased tension, as previously
described (MaassenVanDenBrink et al., 2000). These contractile
responses were evaluated post hoc in the absence (relaxation to bra-
dykinin <18%) or presence (relaxation to bradykinin >18%) of func-
tional endothelium; for this, endothelial function data was divided in
percentiles, where values below the 50th percentile were considered
without endothelium, and above the 50th percentile were considered
with endothelium. Also, segments were preincubated with clinically
relevant concentrations of sumatriptan (0.3 μM) or lasmiditan (1 μM)
and followed by a concentration–response curve to lasmiditan or
sumatriptan, respectively, to evaluate the possible interactions (i.e.,
augmented vasoconstriction) between agonists. The clinically relevant
concentration of sumatriptan was calculated as previously described
(Labruijere et al., 2015); in the case of lasmiditan, it was estimated
based on the Cmax observed in humans following a 100‐mg dose
(0.25 μM; Kovalchin, Ghiglieri, Zanelli, Ings, & Mathers, 2016).2.5 | Correlation between binding (pKi) and the
contractile potency of lasmiditan and other triptans
We related previous (MaassenVanDenBrink et al., 1998;
MaassenVanDenBrink, Reekers, Bax, & Saxena, 2000; Parsons et al.,
1998; van den Broek et al., 2002) and current data obtained (see Sec-
tion 3) to the potency of these compounds to contract the human iso-
lated coronary artery. In case a compound failed to contract the
human coronary artery, a fixed pEC50 value of 5 was set (see Table
S3). Our pKi values used for this correlation are in agreement with
those previously published in the literature (Table S4; Figure S1).2.6 | Animal preparations
Although in vitro experiments with human isolated arteries provide
invaluable information on vasoconstrictive responses in specific vas-
cular beds, to discard haemodynamic changes after systemic adminis-
tration of novel experimental therapeutic compounds, an in vivo model
is necessary. The beagle dog is a well‐accepted species that has been
in use for several years to predict human cardiovascular responses to
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Mangano, & Hickey, 1987). Therefore, a total of 18 adult female bea-
gle dogs (Canis familiaris) were selected from the CorDynamics, Inc.
animal colony. These animals were obtained from Marshall
BioResources (North Rose, NY, USA). Upon receipt at the Biologic
Resources Laboratory (BRL) of the University of Illinois‐Chicago, dogs
were examined by BRL veterinary personnel to ensure acceptable
health status. Veterinary care was provided by the veterinarians and
staff employed by the BRL. Dogs were acclimatized for at least 7 days
prior to use and were pair‐housed in runs (meeting the size require-
ment set forth by the USDA Animal Welfare Act) with various cage‐
enrichment devices. Room temperature set at 18–27°C, humidity at
30–70%, and fluorescent lights timed to give a 12 hr‐light and
12 hr‐dark cycle. Harlan Certified Canine food (25% Protein Diet
#2025C, HarlanTeklad, Madison, WI, USA) was fed daily (500 g·day−1),
and water was freely available in their runs. At the day of their termi-
nal experiment, the animals were 10.0 to 11.5 months old, and their
body weights ranged from 5.4 to 7.9 kg. Body weights were measured
twice (approximately 1 week between measurements) prior to each
animal's terminal procedure. Dogs were fasted for 16–18 hr prior to
dosing.
All experimental protocols were approved and conducted by
CorDynamics in compliance with the U.S. FDA Good Laboratory
Practice guidelines (21 CFR Part 58), the Animal Welfare Act, the
Guide for the Care and Use of Laboratory Animals, and the Office
of Laboratory Animal Welfare. Animal studies are reported in
compliance with the ARRIVE guidelines (Kilkenny, Browne, Cuthill,
Emerson, & Altman, 2010) and with the recommendations made by
the British Journal of Pharmacology (Curtis et al., 2018) and the edito-
rial on reporting animal studies (McGrath & Lilley, 2015). For more
specific details on design and statistical analysis, see Sections 2.7
and 2.8.
2.6.1 | General methods
Dogs were dosed with morphine s.c. (1 mg·kg−1) approximately 10–
20 min prior to administration of propofol anaesthesia i.v. (5–
6 mg·kg−1) to allow tracheal intubation. They were placed on a venti-
lator with isoflurane delivered at 1–2% in oxygen to maintain anaes-
thesia throughout the experiment, and s.c. morphine (0.5 mg·kg−1)
was administered approximately every 2 hr while under anaesthesia.
The local anaesthetic bupivacaine was infiltrated into the incision
sites. A continuous 0.9% NaCl solution for injection drip (approxi-
mately 10 ml·kg−1·hr−1) was maintained until the start of dosing at
which time it was discontinued. Dogs were placed on a heating pad
set to maintain the animal's body temperature at approximately 37°
C, and their body temperature was monitored throughout the experi-
ment by placing a rectal temperature probe. Additionally, surface ECG
leads were placed for anaesthesia monitoring throughout the experi-
mental protocol.
A mid‐lateral neck incision was made and the left common carotid
artery was exposed. A Transonic Systems Inc. (Ithaca, NY, USA) blood
flow probe and two Sonometric Corporation (London, Ontario,Canada) crystals for arterial dimensional analysis were affixed to the
artery. A left lateral thoracotomy (sixth, intercostal space) was per-
formed, and the left circumflex (LCX) coronary artery was exposed.
A Transonic Systems Inc. blood flow probe and two Sonometric Cor-
poration crystals for arterial dimensional analysis were affixed to the
artery. A solid‐state high‐fidelity pressure catheter (Millar Inc., Hous-
ton, TX, USA) for measurement of arterial pressure (mean, MAP; sys-
tolic, SAP; and diastolic, DAP) and heart rate was inserted into a
femoral artery and secured in place with silk suture. An indwelling
catheter was placed into the femoral vein for collecting blood (2 ml)
prior to the start of dosing and at the end of each 20 min infusion
period (see experimental protocol) for bioanalytical analysis.
2.6.2 | Experimental protocol
Upon completion of the general instrumentation, a 15‐min equilibrium
period was allowed for a stable haemodynamic condition. Baseline
values (defined as the average of the three 5‐min values at the afore-
mentioned 15 min) of MAP, heart rate, and carotid and LCX coronary
artery diameter and flow were determined. Subsequently, the 18 dogs
were randomly assigned into three groups (n = 6 each), which received
vehicle (saline), lasmiditan (0.03, 0.13, 1.13, 4.13, and 11.13 mg·kg−1),
or sumatriptan (0.03–11.3 mg·kg−1) respectively. All treatments were
filtered through a 0.2‐μM membrane and administered i.v. in the esca-
lating cumulative doses mentioned above. Dose intervals amongst dif-
ferent treatments were administered each 20 min. At the end of the
experiment, dogs were killed while under anaesthesia via a barbiturate
overdose.2.7 | Sample size calculation, randomization, and
blinding
2.7.1 | Sample size calculation
The animal sample size (n = 6 each group) was calculated by
CorDynamics based on their previous studies (Cushing et al., 2009).
For the in vitro studies, we based the experimental number (n = 5–7
each group) on previous studies from our group (Chan, Baun, et al.,
2011; Labruijere et al., 2015).
2.7.2 | Randomization
For the in vitro experiments, all artery segments were cut into rings
and randomly assigned to a bath, and then the treatment group was
designed by using a table of random numbers.
For the in vivo experiments, the animals initially divided in sets
(n = 6 each group as described above) were randomly assigned to
study groups by CorDynamics staff.
2.7.3 | Blinding
For the radioligand and second messenger assays, the analyst was
not blinded to the compounds but to the research hypothesis. For
6 RUBIO‐BELTRÁN ET AL.BJPthe vascular in vitro experiments, values were calculated using the
dose–response auto‐analyse selection feature of LabChart. During
the analysis, the investigator was unaware of which concentration
response curve was being analysed. The in vivo experimental values
(i.e., the changes in MAP or artery diameter) in each group of ani-
mals were simultaneously obtained by at least two different
CorDynamics investigators, with at least one of the investigators
blinded.2.8 | Data presentation and statistical analysis
All data in the text and figures are presented as the mean ± SEM from
(n) experiments, as shown in the figure legends. The data and statisti-
cal analysis comply with the recommendations of the British Journal of
Pharmacology on experimental design and analysis in pharmacology
(Curtis et al., 2018).2.8.1 | Radioligand binding and second messenger
activity
For binding competition and second messenger activity assays, refer-
ence compounds were tested at several concentrations in duplicate
to obtain a concentration–response curve, and an estimated pEC50
(negative logarithm of the concentration eliciting 50% of the maximal
contractile response, i.e., Emax) or pIC50 value (negative logarithm of
the concentration that displaced 50% of the radioligand) was calcu-
lated using XLFit (IDBS, Guildford, UK). Additionally, the reference
values obtained were compared to historical values obtained from
the same receptor and used to validate the experimental session. A
session was considered as valid only if the reference value was found
to be within a 0.5 log interval from the historical value, for assays
where historical values (determined in at least five experiments) were
available (Abourashed, Koetter, & Brattström, 2004; Barac et al., 2012;
Sun, Blanton, Gabriel, & Canney, 2005). For the new assays developed
in this study (i.e., 5‐ht1E receptor), the two independent pIC50 deter-
mined must be concordant with a 1 log unit interval for the assays
to be validated. When less than 50% inhibition of binding or second
messenger activation was obtained at 10 μM, a pIC50/pEC50 of “<5”
was set2.8.2 | Experiments with human isolated arteries
For the in vitro studies using human blood vessels, concentration–
response curves were analysed using GraphPad software (GraphPad
Software Inc., San Diego, CA, USA; RRID:SCR_002798) to determine
pEC50 values as previously reported (Labruijere et al., 2015). When a
plateau in the concentration–response curve was not reached, the
response observed with the highest concentration used (i.e.,
100 μM) was considered as Emax. Differences between pEC50 and Emax
values of the compounds were evaluated with Tukey's test, once an
ANOVA for paired data had revealed that the samples representeddifferent populations. Values of P < .05 were considered to indicate
significant differences.2.8.3 | In vivo studies
In the in vivo studies, each haemodynamic parameter was analysed
with a repeated measure analysis of covariance (RANCOVA) for
changes from baseline at time intervals of 5, 10, 15, and 20 min for
each of the five dose levels. The model factored the treatment
(TRT), the time after dose (TIME), and the interaction of time after
dose with treatment (TRT * TIME). The SAS® procedure PROC
MIXED was used for analysis with TIME as the repeated effect and
ANIMAL as the subject. The covariance between errors from the same
animal at different time points was selected based on the corrected
Akaike's information criterion from selected covariance structures of
VC, AR(1), UN, and CS. Non‐monotonic dose–responses were evalu-
ated. Within the framework of the RANCOVA, comparisons were
made for vehicle‐ versus lasmiditan‐treated animals and for vehicle‐
versus sumatriptan‐treated animals. If TRT * TIME was significant,
the comparisons were conducted for each time interval using an anal-
ysis of covariance (ANCOVA) model with an effect for treatment and
baseline as a covariate. If only theTRT effect was significant, the com-
parison was conducted across the pooled time intervals for the overall
phase only. These non‐monotonic treatment group comparisons were
conducted at the P = .01 significance level. Baseline data were
analysed with an ANOVA for each time interval. Factors in the model
included treatment (TRT). All statistical analyses were conducted with
SAS® version 9.2 (RRID:SCR_008567). After the database lock, post
hoc analyses for coronary artery diameter and carotid artery diameter
(primary endpoints) at the clinically relevant time interval 20 min (com-
pletion of dose administration) for each cumulated dose (0.03–
11.13 mg·kg−1) were performed for comparisons between sumatriptan
and vehicle. A significance level of P ≤ .025 was used for the
RANCOVA using Bonferroni correction of two tests (coronary and
carotid artery diameter).2.9 | Materials
The compounds used in the present study (obtained from the sources
indicated) were 5‐HT hydrochloride, naratriptan hydrochloride,
almotriptan malate, avitriptan fumarate, and sumatriptan succinate
(Sigma Chemical Co., St. Louis, MO, USA); lasmiditan hemisuccinate
(Eli Lilly & Co., Indianapolis, IN, USA); 5‐CT maleate, sumatriptan suc-
cinate, zolmitriptan, rizatriptan benzoate, eletriptan hydrobromide,
donitriptan hydrochloride, LY334370 hydrochloride, and LY344864
hydrochloride (Tocris Bioscience Co., Park Ellisville, MO, USA); ergot-
amine tartrate (TEVA Pharmaceutical Industries Ltd., Petach Tivka,
Israel); and alniditan salt (kind gift of Janssen Pharmaceutica, Beerse,
Belgium).
All compounds were dissolved in distilled water or physiological
saline for the in vitro and in vivo studies respectively. These vehicles
had no effect on the baseline MAP values or artery diameter (not
RUBIO‐BELTRÁN ET AL. 7BJPshown). Fresh solutions were prepared for each experiment. The
doses mentioned in this text refer to the free base of substances.2.10 | Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corre-
sponding entries in http://www.guidetopharmacology.org, the com-
mon portal for data from the IUPHAR/BPS Guide to
PHARMACOLOGY (Harding et al., 2018), and are permanently
archived in the Concise Guide to PHARMACOLOGY 2017/18
(Alexander et al., 2017).3 | RESULTS
3.1 | Pharmacological characterization of lasmiditan
As shown inTable 1, radioligand studies revealed that lasmiditan selec-
tively binds to the human 5‐HT1F receptor. On the other hand, the
triptans almotriptan, avitriptan, eletriptan, frovatriptan, naratriptan,
sumatriptan, and zolmitriptan showed affinity also for 5‐HT1B, 5‐
HT1D, and 5‐HT1F receptors, while alniditan, donitriptan, ergotamine,
and rizatriptan had affinity for 5‐HT1B and 5‐HT1D receptors. Most
importantly, when analysing their second messenger activity, we
observed that ergotamine is an agonist of the 5‐HT1A/B/D, 5‐HT2A/B,
and 5‐HT7 receptors (but not of 5‐HT1F receptors). Similarly, sumatrip-
tan, zolmitriptan, naratriptan, almotriptan, eletriptan, frovatriptan, and
avitriptan are agonists of the 5‐HT1B/D receptors and also of the 5‐
HT1F receptor. Lasmiditan, as well as LY344864, displayed a high
potency only for the 5‐HT1F receptor (Table 2). In Figure 1, theTABLE 1 Summary of pIC50 (negative logarithm of the molar concentrat
and pKi (negative logarithm of the molar concentration of the Ki) values o
Agonist
5‐HT1A 5‐HT1B 5‐HT1D 5‐ht1
pIC50 pKi pIC50 pKi pIC50 pKi pIC50
Ergotamine tartrate 9.19 9.70 8.87 9.34 8.63 9.31 6.08
Sumatriptan succinate 6.63 7.14 7.81 8.29 8.31 9.00 5.42
Zolmitriptan 7.28 7.79 8.85 9.33 9.28 9.97 7.51
Naratriptan hydrochloride 7.31 7.82 8.75 9.22 8.62 9.30 7.83
Rizatriptan benzoate 6.81 7.32 7.51 7.99 8.15 8.83 6.48
Almotriptan malate 6.23 6.73 7.97 8.45 7.57 8.26 <5
Eletriptan hydrobromide 8.20 8.71 8.80 9.28 9.31 9.99 6.91
Frovatriptan racemate 6.83 7.34 8.09 8.57 8.10 8.78 <5
Donitriptan hydrochloride 7.42 7.93 9.29 9.77 9.18 9.86 5.47
Avitriptan fumarate 7.20 7.71 8.32 8.80 8.42 9.11 5.15
Alniditan dihydrochloride 8.81 9.32 8.93 9.41 8.66 9.35 5.98
Lasmiditan hemisuccinate 5.88 6.39 5.54 6.02 5.62 6.31 5.54
LY334370 hydrochloride 7.98 8.49 6.74 7.21 6.24 6.92 6.83
LY344864 hydrochloride 6.12 6.63 6.13 6.61 5.83 6.52 6.05
Note. The lesser than symbol (<) indicates that less than 50% inhibition of bindi
are described in Table S1.agonistic profile of the different antimigraine drugs tested on the 5‐
HT1B/D/F receptors (i.e., relevant for migraine therapy) are represented.
When comparing our results with those previously published, our
values are in agreement with those in the literature (seeTables S4–S5;
Figure S1). Moreover, no functional responses to 5‐CT were observed
in the CHO‐K1 cells transfected with an unrelated GPCR (Figure S2).3.2 | Human isolated arteries
In the human isolated coronary arteries, sumatriptan induced signifi-
cant contractions in a concentration‐dependent manner in the proxi-
mal (Emax 39 ± 12%, pEC50 6.4 ± 0.2; n = 6) and distal (Emax
59 ± 41%, pEC50 6.02 ± 0.2; n = 6) coronary segments, even at clini-
cally relevant concentrations (see Figure 2). In contrast, as compared
with vehicle, lasmiditan was devoid of any significant contractile
effects in both coronary segments, even at its highest concentration
(100 μM, supratherapeutic; Emax 1 ± 1%).
Moreover, Figure 3 shows the effects of lasmiditan and sumatrip-
tan on internal mammary arteries in the absence and presence of
endothelium. Sumatriptan induced concentration‐dependent contrac-
tions in blood vessels with (Emax 46 ± 18%, pEC50 6.07 ± 0.07;
n = 5) and without functional endothelium (Emax 31 ± 12%, pEC50
5.6 ± 0.94; n = 7). After precontraction with threshold concentrations
of U46619, sumatriptan also produced concentration‐dependent con-
tractions in the presence (Emax 63 ± 19%, pEC50 6.83 ± 0.05; n = 5) and
absence (Emax 59 ± 16%, pEC50 6.02 ± 0.59; n = 7) of functional endo-
thelium. In marked contrast, vehicle and lasmiditan were devoid of any
significant contractile effects in internal mammary arteries (Emax
1 ± 1% without endothelium; Emax 0 ± 0% with endothelium), evenion of these compounds at which 50% of the radioligand is displaced)
f individual antimigraine drugs at 5‐HT receptors
E 5‐HT1F 5‐HT2A 5‐HT2B 5‐HT7
pKi pIC50 pKi pIC50 pKi pIC50 pKi pIC50 pKi
6.39 6.71 7.13 7.62 8.14 7.73 7.94 7.13 7.23
5.72 7.13 7.55 <5 <5 <5 <5 6.10 6.19
7.81 7.13 7.55 <5 <5 <5 <5 6.97 7.06
8.13 8.33 8.75 <5 <5 <5 5.08 5.84 5.93
6.78 6.4 6.82 <5 <5 5.30 5.51 <5 <5
<5 7.15 7.57 <5 <5 <5 <5 6.36 6.46
7.21 7.35 7.77 5.42 5.94 6.14 6.35 6.61 6.70
5.18 6.50 6.92 <5 <5 <5 <5 6.88 6.97
5.77 <5 5.18 5.83 6.35 5.88 6.09 6.12 6.21
5.45 6.69 7.11 5.11 5.63 5.73 5.94 6.03 6.12
6.28 6.02 6.44 <5 5.43 6.67 6.88 7.16 7.26
5.84 8.09 8.51 <5 <5 5.01 5.22 <5 <5
7.13 9.03 9.45 5.11 5.63 5.98 6.19 5.66 5.75
6.35 8.38 8.80 5.11 5.63 5.31 5.52 5.69 5.78
ng was obtained at 10 μM. The radioligands used and their concentrations
TABLE 2 Summary of pEC50 values of cAMP (5‐HT1A/B/E/F and 5‐HT7), GTPγS (5‐HT1A/B/D/E/F), and IP (5‐HT2) assays of individual antimigraine
drugs at 5‐HT receptors
Agonist
5‐HT1A 5‐HT1B 5‐HT1D 5‐ht1E 5‐HT1F 5‐HT2A 5‐HT2B 5‐HT7
cAMP GTPγS cAMP GTPγS GTPγS cAMP GTPγS cAMP GTPγS IP IP cAMP
Ergotamine tartrate 9.78 9.63 9.94 9.52 9.43 5.95 5.74 5.97 6.30 9.25 8.72 7.09
Sumatriptan succinate <5 <5 7.32 7.91 8.30 5.99 5.79 8.03 6.80 <5 <5 5.22
Zolmitriptan <5 5.52 7.87 8.42 9.51 8.18 7.81 8.00 6.67 <5 <5 6.28
Naratriptan hydrochloride <5 6.52 8.05 8.86 8.80 7.75 8.17 8.38 8.05 <5 <5 <5
Rizatriptan benzoate <5 <5 7.08 7.56 8.11 7.34 6.90 6.54 5.91 <5 5.49 <5
Almotriptan malate <5 5.48 7.08 7.85 7.75 <5 <5 7.79 6.90 <5 5.20 <5
Eletriptan hydrobromide 5.74 6.38 8.00 8.09 9.04 7.53 6.90 8.13 6.88 6.07 6.81 6.45
Frovatriptan racemate <5 6.12 7.98 8.14 8.36 5.04 <5 7.10 6.35 <5 <5 7.42
Donitriptan hydrochloride 5.94 6.74 9.96 9.52 9.51 <5 <5 <5 <5 8.10 7.61 5.23
Avitriptan fumarate <5 6.19 8.57 8.68 9.27 5.52 <5 7.09 6.05 6.91 6.41 5.38
Alniditan dihydrochloride 7.00 7.29 8.87 8.90 8.20 5.68 5.21 5.92 5.17 <5 7.15 6.32
Lasmiditan hemisuccinate <5 <5 <5 <5 6.64 6.17 5.34 8.43 7.80 <5 <5 <5
LY334370 hydrochloride 5.84 6.96 6.52 5.80 6.92 7.53 6.95 9.08 9.38 <5 <5 <5
LY344864 hydrochloride <5 <5 <5 5.82 6.93 6.22 6.12 8.72 7.85 <5 <5 <5
Note. These values represent the negative logarithm of the molar concentration of these compounds at which 50% of their maximal response is exerted.
The lesser than symbol (<) indicates that less than 50% response was obtained at 10 μM. The reference compounds used and their concentrations are
described in Table S2.
FIGURE 1 Summary of the agonist profiles (pEC50 > 7) of the antimigraine drugs tested on the 5‐HT1B, 5‐HT1D, and 5‐HT1F receptors. Redrawn
from Rubio‐Beltran, Labastida‐Ramirez, Villalon, and MaassenVanDenBrink (2018)
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FIGURE 2 Contractile responses to lasmiditan and sumatriptan (1 nM–100 μM) in the isolated human proximal (left) and distal (right) coronary
arteries; *P < .05, significantly different as indicated; n = 6 each
FIGURE 3 Contractile responses to sumatriptan and lasmiditan (1 nM–100 μM) in the absence (left) and presence (right) of a threshold
precontraction with U46619 (1–10 nM) in the isolated human internal mammary arteries with (upper panel, n = 5) and without (lower panel,
n = 7) functional endothelium; *P < .05, significantly different as indicated
RUBIO‐BELTRÁN ET AL. 9BJPafter a modest precontraction with U46619 (Emax 0 ± 1% without
endothelium; Emax 1 ± 1% with endothelium).
In the middle meningeal artery, sumatriptan induced significant
concentration‐dependent contractions (Emax 73 ± 13%, pEC50
6.32 ± 0.15; n = 6), whereas lasmiditan did not induce any significant
contraction at all concentrations tested (Emax 0 ± 0%, Figure 4).4 | INTERACTION EXPERIMENTS
As shown in Figure 5, in the internal mammary arteries, after
preincubation with lasmiditan (1 μM), no changes in the contractile
responses to sumatriptan were observed when compared to the
concentration–response curve to sumatriptan alone (Emax 59 ± 16%,
pEC50 5.34 ± 0.1 vs. Emax 51 ± 19%, pEC50 5.71 ± 0.7; n = 5 each).
In addition, the highest concentration of lasmiditan produced a non‐
significant vasodilation when preincubated with sumatriptan's clini-
cally relevant concentration (0.3 μM) when compared to the
concentration–response curve to lasmiditan without sumatriptan
(Emax − 4.8 ± 5.95% vs. Emax 0 ± 0%; n = 5 each).4.1 | Correlation between binding (pKi) and the
contractile potency of lasmiditan and other triptans
As shown in Figure 6, the potency of the compounds tested to con-
tract the human isolated coronary artery was positively correlated
with their potency to bind the 5‐HT1B receptor, whereas it was nega-
tively correlated for the 5‐HT1F receptor. This was also observed
when correlating the pEC50 values obtained in our second messenger
assays and the contractile potency of the compounds tested in the
human coronary arteries (Figure S3).4.2 | In vivo studies
In anaesthetised dogs, a directly proportional relationship was
observed between lasmiditan and sumatriptan cumulative i.v. doses
and their plasma concentrations; these latter values were used for val-
idating the concentrations used in the in vitro studies (data not shown).
Moreover, as shown in Figure 7, changes in carotid artery diameter
were not statistically significant in the lasmiditan‐treated group as
FIGURE 4 Contractile responses to sumatriptan and lasmiditan
(1 nM–100 μM) in the isolated human middle meningeal arteries;
*P < .05, significantly different as indicated; n = 6 each
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expected, sumatriptan induced dose‐dependent decreases in carotid
artery diameter, although these effects were statistically significant
only at the doses of 0.13 mg·kg−1 (clinically relevant) and
11.13 mg·kg−1 (Figure 7). In the LCX coronary artery, lasmiditan failed
to induce any statistically significant change in diameter at any dose.
Conversely, statistically significant decreases in the LCX coronary
artery diameter were observed at all doses in sumatriptan‐treated ani-
mals as compared to the time‐matched vehicle control animals, even
at the lowest dose of 0.03 mg·kg−1, which already corresponds to a
clinically relevant dose.
Carotid blood flow was not significantly different after vehicle or
clinically relevant doses of lasmiditan (0.03–1.13 mg·kg−1). Lasmiditan
decreased carotid blood flow significantly, but only after the
supratherapeutic cumulative doses of 4.13 and 11.13 mg·kg−1. In
contrast, sumatriptan elicited a statistically significant rapid, dose‐
dependent, decrease in carotid blood flow at all doses tested.FIGURE 5 Contractile responses to sumatriptan and lasmiditan (1 nM–1
clinically relevant concentration of sumatriptan (0.3 μM) or lasmiditan (1 μ
sumatriptan, respectively (n = 6 each)Regarding coronary blood flow, the administration of vehicle,
lasmiditan, or sumatriptan did not elicit any statistically significant
changes (data not shown).
Heart rate was stable over the course of the study, and no
significant changes were observed in the lasmiditan or vehicle groups.
In the sumatriptan‐treated group, cumulative doses of 4.13 and
11.13 mg·kg−1 elicited dose‐dependent decreases in heart rate, which
were statistically significant, with a peak decrease at 90 min of
16.5 ± 6 bpm (data not shown). MAP, SAP, and DAP showed no signif-
icant changes in either sumatriptan or lasmiditan‐treated groups as
compared to the time‐matched vehicle group at cumulative doses of
up to 4.13 mg·kg−1. At higher doses, both lasmiditan‐ and
sumatriptan‐treated groups showed a dose‐dependent trend to
decrease MAP, SAP, and DAP; however, these changes were not sta-
tistically significant (Figure 7).5 | DISCUSSION
The current study was designed to investigate the selectivity and
vasoconstrictor profile of lasmiditan, which belongs to a novel class
of acute antimigraine drugs, the ditans. According to its binding and
functional activity, it was confirmed that lasmiditan is a highly selec-
tive agonist of the 5‐HT1F receptor. Moreover, as lasmiditan was
developed based on the premise that coronary vasoconstriction is a
side effect of the triptans attributed to 5‐HT1B receptors, we studied
the vasoconstrictor potential of 5‐HT1F agonism in two different vas-
cular models and compared our in vitro and in vivo results to those
obtained with sumatriptan, since this is the “gold standard” triptan
for acute antimigraine treatment. This allowed us to compare the
results from the current study with results obtained earlier. In accor-
dance with our previous work (Chan et al., 2014), sumatriptan induced
a concentration‐dependent contraction in human isolated coronary
arteries, which tended to be larger in distal than in proximal coronary
artery segments. This contraction was apparent at clinically relevant
concentrations and is most likely due to activation of 5‐HT1B receptors
in vascular smooth muscle (Chan et al., 2014). In contrast, lasmiditan00 μM) in the internal mammary artery, after preincubation with the
M), and followed by a concentration–response curve to lasmiditan or
FIGURE 6 Correlation between the pKi values obtained in our study and the contractile potency of lasmiditan, triptans (sumatriptan,
zolmitriptan, naratriptan, rizatriptan, eletriptan, frovatriptan, donitriptan, and avitriptan), and other 5‐HT receptors ligands (ergotamine, alniditan,
5HT, and 5‐carboxamidotryptamine) in human isolated coronary arteries; N.S., non‐significant; *P < .05, significant correlation
RUBIO‐BELTRÁN ET AL. 11BJPdid not induce a contraction at concentrations up to 100 μM (≥100×
the clinically relevant concentrations) in either proximal or distal coro-
nary arteries. Although moderate to intense expression of mRNA
encoding the 5‐HT1F receptor in human coronary arteries has been
described (Nilsson et al., 1999), the presence of mRNA does not neces-
sarily mean protein expression, which may well be the case. Thus, the
physiological role of this receptor in blood vessels remains to be
determined.
Subsequently, we performed more in‐depth experiments in the
internal mammary artery, where we studied the influence of endothe-
lial functional quality, and the effects of a precontraction induced by
the TxA2 analogue U46619, as such a precontraction is known to
“unmask” or augment contractions to other ligands, such as sumatrip-
tan (MaassenVanDenBrink, van den Broek, de Vries, Upton, et al.,
2000). As observed in the coronary artery, sumatriptan contracted
the internal mammary artery, similarly in both segments with and
without functionally active endothelium. In accordance with earlier
observations (MaassenVanDenBrink, van den Broek, de Vries, Upton,
et al., 2000), the contractions to sumatriptan were augmented in the
presence of U46619. In contrast, lasmiditan did not induce any con-
traction in the absence or presence of U46619 in either vessel seg-
ments with or without endothelium. Interestingly, in the rabbit
saphenous vein, precontraction with PGF2α unmasked a contractile
response to the 5‐HT1F receptor agonists, LY334370 and LY344864,
but only after high concentrations (>10 μM), and therefore likely due
to activation of vascular 5‐HT1B receptors (Cohen & Schenck, 2000).Hence, the absence of contractile responses with high concentrations
of lasmiditan, even in precontracted vessels, is surprising, given the
difference in affinity between sumatriptan and lasmiditan to the 5‐
HT1B receptor. However, binding affinity does not always correlate
with second messenger activation and biological response (Colquhoun,
1998). Therefore, while our radioligand studies (Table 1) showed a
~100‐fold binding difference to the 5‐HT1B receptor between suma-
triptan (pIC50 = 7.81) and lasmiditan (pIC50 = 5.54), our cAMP assays
(Table 2) showed that the functional potency (pEC50) of sumatriptan
was 7.32 and lasmiditan was <5. As we could not determine the pre-
cise pEC50 value of lasmiditan, the potency difference between both
compounds could be larger than 1,000‐fold and thus explain the com-
plete absence of vasoconstrictive responses even at supra‐therapeutic
concentrations such as 100 μM. This could represent a cardiovascular
safety advantage over its triptan predecessors.
Additionally, as contraction of the meningeal artery is thought to
contribute to the antimigraine effects of the triptans (Benemei et al.,
2017; Chan, Vermeersch, de Hoon, Villalón, & MaassenVanDenBrink,
2011; Rubio‐Beltran et al., 2018), but is not a class effect of all
antimigraine drugs (e.g., gepants), we investigated the contractions to
sumatriptan and lasmiditan in human meningeal arteries. In accordance
to the previously described craniovascular selectivity of the triptans
(MaassenVanDenBrink et al., 2000; van den Broek et al., 2002), con-
tractions to sumatriptan were larger in this dural artery than those in
the proximal coronary artery. However, as we have also previously
shown, contractions to sumatriptan in distal coronary artery (and
FIGURE 7 Changes in the left circumflex
(LCX) coronary artery diameter (a), carotid
artery diameter (b), and mean arterial blood
pressure (c) after the continuous infusion of
lasmiditan and sumatriptan (0.03–
11.13 mg·kg−1 each) or the corresponding
infusion volumes of vehicle in female beagle
dogs (n = 6 each). *P < .05, significantly
different from vehicle; post hoc analysis (see
methods)
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meningeal artery (Chan et al., 2014). In contrast, lasmiditan was
devoid of vascular effects in this cranial vessel. Therefore, the
efficacy of lasmiditan as acute migraine treatment may be due to inhi-
bition of CGRP release from perivascular fibres or direct central
(antinociceptive) modulation (Rubio‐Beltran et al., 2018).
Our binding studies showed that, as mentioned previously, most of
the triptans available in the market, namely, almotriptan, frovatriptan,
naratriptan, sumatriptan, and zolmitriptan, are also agonists of the 5‐
HT1F receptor (Figure 1). Furthermore, the correlation between bind-
ing and the contractile potency of the compounds tested revealed that
the potency of the agonists to contract the HCA positively correlated
to their potency to bind the 5‐HT1B receptor, whereas it negatively
correlated for the 5‐HT1F receptor (Figure 6), and this was also
observed when correlating the contractile potency and secondmessenger activation (Figure S3). Moreover, when analysing the corre-
lation between second messenger activation by 5‐HT1B versus 5‐HT1F
receptors, also a negative correlation was observed (Figure S4). These
results, together with our in vitro data, suggest that although the
mRNA of both receptor subtypes has been described in human vascu-
lature (Bouchelet et al., 1996; Bouchelet et al., 2000; Chan et al., 2009;
Chan et al., 2014; Nilsson et al., 1999; Parsons et al., 1998; van den
Broek et al., 2002), only activation of the 5‐HT1B receptor will result
in vasoconstriction of, at least, coronary, mammary, and meningeal
arteries, whereas activation of the 5‐ HT1F receptor will not. This could
suggest that either 5‐HT1F receptors in human vasculature are not
functional or that 5‐HT1F receptor mRNA is not translated to protein.
When considering the acute haemodynamic effect of sumatriptan
in humans, it is well known that after subcutaneous administration,
there are vasopressor responses in the systemic arterial circulation
RUBIO‐BELTRÁN ET AL. 13BJPand coronary artery vasoconstriction (MacIntyre, Bhargava, Hogg,
Gemmill, & Hillis, 1993). Although we observed carotid and coronary
vasoconstriction in anaesthetized dogs, there were no significant
increases in blood pressure, as previously reported in this animal
model (Villalón & Terrón, 1994). In fact, after high doses of sumatrip-
tan, a non‐significant tendency to decrease blood pressure and signif-
icant decreases in heart rate were observed, most probably due to
inhibition of vascular and cardiac sympathetic outflows via the stimu-
lation of prejunctional 5‐HT1B/1D receptors on perivascular (Villalón
et al., 1998) and cardiac (Sánchez‐López et al., 2003; Sánchez‐López
et al., 2004) sympathetic nerves. Lasmiditan only showed a trend to
decrease blood pressure at the highest (supratherapeutic dose), which,
based on the affinity of lasmiditan (seeTable 1), could be due to a non‐
selective activation of prejunctional 5‐HT1D receptors and subsequent
inhibition of sympathetic perivascular nerves (Villalón et al., 1998).
Admittedly, this has not been shown directly in dogs but in pithed
Wistar rats, and, in patients, no changes in blood pressure have been
observed (Farkkila et al., 2012; Ferrari et al., 2010). Further experi-
ments, falling beyond the scope of the present study, would be
required to shed more light on the mechanisms behind these
responses, which are only observed at non‐clinically relevant doses.
In summary, our in vitro and in vivo results indicate that lasmiditan
is devoid of contractile properties in isolated human and anaesthetized
dog arteries respectively. This might be of particular relevance in
migraine patients who have a high risk of developing cardiovascular
disease, such as subjects with hemiplegic migraine, prolonged migraine
with aura, or with established cardiovascular disease. Clearly, further
studies are needed to evaluate the safety of lasmiditan in these spe-
cific patient populations and its effectiveness compared with triptans.
Finally, clinical trials have shown that lasmiditan is effective for
migraine treatment (Goadsby et al., 2019; Kuca et al., 2018), suggest-
ing a mechanism of action (partly) different to that of the triptans
(Rubio‐Beltran et al., 2018).
In conclusion, our data support our initial hypothesis that
lasmiditan is a high‐affinity and highly selective agonist for the human
5‐HT1F receptor that is devoid of contractile properties in human iso-
lated blood vessels and in anaesthetized canines.
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